ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ACPA"

  • Abstract Number: 2289 • 2013 ACR/ARHP Annual Meeting

    Correlation Of Anti-Citrullinated Protein and Anti-Carp Antibodies With Disease Duration and Activity In Rheumatoid Arthritis

    Michael Mahler1, Gabriella Lakos1, Tyler Webb1, Alvin Yee1, Leendert A. Trouw2 and Pier-Luigi Meroni3, 1Research, INOVA Diagnostics, San Diego, CA, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Int Medicine, University of Milan, Milano, Italy

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are important serological markers in the diagnosis of rheumatoid arthritis (RA) and are part of the…
  • Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting

    Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study

    Takao Fujii1, Masahiro Sekiguchi2, Kiyoshi Matsui2, Masayasu Kitano2, Motomu Hashimoto3, Koichiro Ohmura4, Aihiro Yamamoto5, Hideko Nakahara6, Keiji Maeda7, Akira Yokota8, Kenji Miki9, Naoki Shimmyo10, Takanori Kuroiwa11, Kosaku Murakami12, Yoshio Ozaki13, Kenshi Higami14, Ichiro Yoshii15, Yuji Nozaki16, Takashi Ikawa17, Satoshi Morita18, Yutaka Kawahito5, Norihiro Nishimoto19, Tsuneyo Mimori4 and Hajime Sano2, 1Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, 3The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 6Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 7Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 8Yokota Clinic for Rheumatology, Osaka, Japan, 9Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, 10Kashiba Asahigaoka Hospital, Kashiba, Japan, 11Department of Rheumatology, Yukioka Hospital, Osaka, Japan, 12Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Kansai Medical University Hirakata Hospital, Hirakata, Japan, 14Department of Rheumatology, Higami Hospital, Nara, Japan, 15Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, 16Kinki University Faculty of Medicine, Sayama, Japan, 17Osaka Rehabilitation Hospital, Hannan, Japan, 18Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, 19Osaka Rheumatology Clinic, Osaka, Japan

    Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
  • Abstract Number: 2260 • 2013 ACR/ARHP Annual Meeting

    Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis

    Bjorn Svensson1, Ingiäld Hafström2, Malin Erlandsson3, Kristina Forslind4 and Maria Bokarewa3, 1Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, 2Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, 3Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden

    Background/Purpose: High levels of the oncoprotein survivin may be detected in the majority of patients with early rheumatoid arthritis (RA). Survivin is a sensitive predictor…
  • Abstract Number: L13 • 2013 ACR/ARHP Annual Meeting

    Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients

    D. van Schaardenburg1, Marian van Beers-Tas2, Karin Britsemmer2, Mairead Murphy3, Walter P. Maksymowych4, Maarten Boers5 and Anthony Marotta6, 1Jan van Breemen Research Institute, Amsterdam, Netherlands, 2Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Augurex Life Sciences Corp., North Vancouver, BC, Canada, 4Department of Medicine, University of Alberta, Edmonton, AB, Canada, 5Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, 6Augurex Life Sciences Corp, North Vancouver, BC, Canada

    Background/Purpose: The focus of RA management is increasingly towards early detection and treatment. While newly-diagnosed patients will benefit from treatment decisions based on more robust…
  • Abstract Number: 2244 • 2013 ACR/ARHP Annual Meeting

    Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a  Population Based Cohort

    Aase Haj Hensvold1, Patrik KE Magnusson2, Lena Israelsson3, Monika Hansson4, Vijay Joshua1, Rikard Holmdahl5, Per-Johan Jakobsson3, Johan Askling6, Vivianne Malmström7, Lars Klareskog3 and Anca I Catrina3, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Medical Epidemiology and Biostatistics, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, 3Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 6Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 7Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Anti-CCP testing is a part of the clinical routine investigations for rheumatoid arthritis (RA). Previous studies have relative few included controls per patients. We therefor…
  • Abstract Number: 2224 • 2013 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor Alpha Induces Anti-Citrullinated Protein Antibodies and Arthritis In Part Through Peptidyl Arginine Deiminase 4

    Miriam A. Shelef1, Jeremy Sokolove2, Catriona Wagner3, Eric Sackmann4, Thomas Warner5, David Beebe4, William H. Robinson6 and Anna Huttenlocher7, 1Medicine, Univ of Wisconsin Schl of Med, Madison, WI, 2VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 3VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 4Materials Science Program and Department of Biomedical Engineering, University of Wisconsin, Madison, WI, 5Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, 6VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7Dept of Pediatrics and MMI, Univ of Wisconsin Schl of Med, Madison, WI

    Background/Purpose: Rheumatoid arthritis is an autoimmune, destructive arthritis characterized by anti-citrullinated protein antibodies (ACPAs) and high levels of inflammatory cytokines like tumor necrosis factor alpha…
  • Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting

    Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients

    Hitoshi Uga1, Takahiro Okazawa1, Yoshiaki Miyamoto1, Takehiro Hasegawa1, Jun Saegusa2, Goh Tsuji3, Sho Sendo4, Akio Morinobu5, Shunichi Kumagai6,7 and Hirokazu Kurata1, 1Sysmex Corporation, Kobe, Japan, 2Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 3Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, 4Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, 5Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Center of rheumatic diseases, Shinko hospital, Kobe, Japan, 7Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
  • Abstract Number: 1875 • 2013 ACR/ARHP Annual Meeting

    A Dense Mapping Of Human Leukocyte Antigen Region For Study Of Interaction With Smoking In The Development Of Rheumatoid Arthritis

    Xia Jiang1, Henrik Källberg1, Lisbeth Ärlestig2, Solbritt M. Rantapää-Dahlqvist3, Lars Klareskog4, Leonid Padyukov5 and Lars Alfredsson6, 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 6Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is believed to have a multifactorial etiology, involving both genetic and environmental components, and can be divided into two major subsets…
  • Abstract Number: 1839 • 2013 ACR/ARHP Annual Meeting

    Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis

    Akilan Krishnamurthy1, Heidi Wähämaa1, Vijay Joshua1, Catia Cerqueira1, Elena Ossipova2, Nancy Vivar Pomiano3, Karin Lundberg2, Vivianne Malmström4, Per-Johan Jakobsson5, Lars Klareskog5, Georg Schett6, Jimmy Ytterberg1 and Anca I Catrina5, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 5Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 6Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Anti citrullinated modified vimentin antibodies isolated from peripheral blood (PB) of RA patients induce osteoclasts (OC) formation from PB derived monocytes of healthy individuals.…
  • Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting

    91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies

    Walter P. Maksymowych1, Dirkjan van Schaardenburg2, Désirée van der Heijde3, Robert Landewé4, Gilles Boire5, Maarten Boers6, Vivian P. Bykerk7, Edward C. Keystone8, Katherine A. Siminovitch9, Mairead Murphy10 and Anthony Marotta11, 1Medicine, University of Alberta, Edmonton, AB, Canada, 2Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, 5Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 6Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, 7Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 8Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 9Mount Sinai Hospital, Toronto, ON, Canada, 10Augurex Life Sciences Corp., North Vancouver, BC, Canada, 11Augurex Life Sciences Corp, North Vancouver, BC, Canada

    Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…
  • Abstract Number: 177 • 2013 ACR/ARHP Annual Meeting

    Differences and Overlap Of Immunological Pathways Implicated In The Aetiology Of Anti-Citrullinated Peptide Antibody Positive and Negative Rheumatoid Arthritis

    Sebastien Viatte1, Paul Martin2, Andrew Brass3, Mark Lunt4, Anne Barton5 and Stephen Eyre5, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3School of Computer Science, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 4Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Genome-wide association studies have been successful in identifying single nucleotide polymorphisms (SNPs) associated with disease. However, previous studies have been under-powered to detect differences…
  • Abstract Number: 1421 • 2013 ACR/ARHP Annual Meeting

    Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study

    Yutaka Kawahito1, Takao Fujii2, Akira Yokota3, Hideo Hashimoto4, Kiyoshi Matsui5, Kenji Miki6, Masayasu Kitano5, Naoki Shinmyo7, Aihiro Yamamoto1, Koichiro Ohmura8, Takanori Kuroiwa9, Toshihiko Hidaka10, Ichiro Yoshii11, Hideko Nakahara12, Takashi Fujimoto13, Kosaku Murakami14, Satoshi Morita15, Masahiro Sekiguchi5, Norihiro Nishimoto16,17, Tsuneyo Mimori8 and Hajime Sano5, 1Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Yokota Clinic for Rheumatology, Osaka, Japan, 4Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, 6Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, 7Kashiba Asahigaoka Hospital, Kashiba, Japan, 8Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 9Department of Rheumatology, Yukioka Hospital, Osaka, Japan, 10Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 11Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, 12Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, 13Nara Medical University, Kashihara, Japan, 14Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, 15Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, 16Tokyo Medical University, Tokyo, Japan, 17Osaka Rheumatology Clinic, Osaka, Japan

    Background/Purpose:  The identification of predictors of good response to biologic therapy is needed in the perspective of personalized medicine. To determine the predicting factors of efficacy…
  • Abstract Number: 2819 • 2013 ACR/ARHP Annual Meeting

    Administration Of a Multi-Epitope Citrullinated Peptide Attuneuates adjuvant  Induced Arthritis In Rats Via Induction Of Immune Tolerance

    Howard Amital1, Smadar Gertel2 and Yehuda Shoenfeld3, 1The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 2The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel, 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel

    Background/Purpose: Antigen-induced peripheral tolerance is a potentially efficient and specific therapeutic approach to attenuate autoimmunity. Citrullinated peptides are major targets of disease-specific autoantibodies in Rheumatoid…
  • Abstract Number: 1389 • 2013 ACR/ARHP Annual Meeting

    Serum 14-3-3η Precedes and Independently Predicts The Development Of RA

    Dirkjan van Schaardenburg1, Reetinder Dhaliwal1, Walter P. Maksymowych2 and Anthony Marotta3, 1Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Medicine, University of Alberta, Edmonton, AB, Canada, 3Augurex Life Sciences Corp, North Vancouver, BC, Canada

    Background/Purpose: We have previously reported on a risk prediction rule for the development of rheumatoid arthritis (RA) in 374 seropositive (RF and/or ACPA) arthralgia patients,…
  • Abstract Number: 2659 • 2013 ACR/ARHP Annual Meeting

    Antibodies To Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markers Of Endothelial Dysfunction In First-Degree Relatives Of Patients With Rheumatoid Arthritis: The Studies Of The Etiology Of Rheumatoid Arthritis

    Jan M. Hughes-Austin1, Kendra A. Young2, Kevin D. Deane3, Michael H. Weisman4, Jane H. Buckner5, Ted R. Mikuls6, James R. O'Dell7, Richard M. Keating8, Peter K. Gregersen9, Jeremy Sokolove10, William H. Robinson11, V. Michael Holers12 and Jill M. Norris2, 1Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, 2Epidemiology, Colorado School of Public Health, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 8Rheumatology Section, The University of Chicago, Chicago, IL, 9Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 10VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 11Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 12Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Among rheumatoid arthritis (RA) patients, antibodies to citrullinated protein antigens (ACPA) have been detected in atherosclerotic plaques. In particular, antibodies to citrullinated fibrinogen (cit-fib)…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology